ParagonRx® | Minimize Risk and Optimize Use

This two-day conference will examine:

• How to more efficiently develop T2DM medications
• How to evaluate CV safety during DM drug development – preclinical and clinical approaches
• Clinical implications and benefits of glycemic control
• Therapies and targets for treatment of Diabetes Mellitus
• Evidence for positive and negative impacts on CV and renal outcomes in Type 2 DM
• Novel trial design approaches to assessing CV safety
• Clinical evidence that T2DM diabetic drugs can increase CV risk and potential mechanisms
• Approaches to the clinical analysis of CV risk
• Clinical approaches to Phase 3 development
• Future approaches to assessing T2DM drug development and CV safety
• Preclinical studies and the use of biomarkers to assess CV safety of new chemical entities